logo

Uniqure N.V. (QURE)



Trade QURE now with
  Date
  Headline
4/8/2019 7:10:09 AM UniQure Says FDA Granted Fast Track Designation For AMT-130
2/8/2019 7:37:01 AM UniQure Reports Updated Data In Patients Treated In Phase IIb Study Of AMT-061
2/4/2019 7:10:13 AM UniQure Announces First Patient Treated In HOPE-B Pivotal Trial Of AMT-061 In Patients With Hemophilia B
1/22/2019 7:03:50 AM UniQure Announces FDA Clearance Of IND Application For AMT-130 In Huntington’s Disease
12/3/2018 7:27:48 AM UniQure Announces Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060
11/6/2018 7:19:48 AM UniQure Q3 Net Loss $22.0 Mln Or $0.59 Per Share
10/16/2018 7:09:56 AM UniQure Announces Presentations At Upcoming Annual Meeting Of The European Society Of Gene And Cell Therapy
9/24/2018 7:09:35 AM UniQure Provides Update On Dose-Confirmation Study Of AMT-061; Sees Topline Data To Be Available Before The End Of 2018
9/10/2018 6:00:42 AM Achillion Appoints Paul Firuta To EVP And COO
8/23/2018 7:02:57 AM UniQure Announces First Patient Treated In Dose-Confirmation Study Of AMT-061 In Patients With Hemophilia B
8/8/2018 7:16:13 AM UniQure Q2 Net Loss $20.6 Mln Or $0.57/Shr Vs Loss $21.3 Mln Or $0.83/Shr Last Year
6/28/2018 7:02:33 AM UniQure Enrolls First Patient In Phase III HOPE-B Pivotal Study Of AMT-061 In Patients With Hemophilia B
6/13/2018 7:03:52 AM UniQure Appoints Robert Gut And David Meek To Its Board
5/21/2018 7:07:52 AM UniQure Presents New Data For Clinical Benefit In Hemophilia B Patients With Pre-Existing Anti-AAV5 NABs
5/18/2018 7:05:22 AM UniQure Presents Preclinical Data Demonstrating Advances In The Distribution Of Gene Therapy
5/7/2018 11:58:49 AM UniQure Announces Closing Of Public Offering